<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LOPINAVIR/RITONAVIR</span><br/>(lop-i-na'ver/rit-o-na'ver)<br/><span class="topboxtradename">Kaletra<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiretroviral agent</span>; <span class="classification">protease inhibitor</span><br/><b>Prototype: </b>Saquinavir Mesylate<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg lopinavir/50 mg ritonavir tablets; 400 mg lopinavir/100 mg ritonavir/5 mL suspension</p>
<h1><a name="action">Actions</a></h1>
<p>Lopinavir, an HIV protease inhibitor that inhibits the activity of HIV protease and prevents the cleavage of viral polyproteins
         essential for the maturation of HIV. Ritonavir in the formulation inhibits the CYP3A metabolism of lopinavir, thereby, increasing
         the blood level of lopinavir.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Decreases plasma HIV RNA level; elevates CD4 cell counts as a result of the combined therapy of the two drugs in HIV infected
         patients.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of HIV infection in combination with other antiretroviral agents.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to lopinavir or ritonavir; concurrent administration with drugs that utilize CYP3A or CYP2D6 for metabolism
         (e.g., ergotamine, pimozide); lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic impairment, patients with hepatitis B or C, older adults; pregnancy (category C). Safety and efficacy in children
         
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">HIV InfectionTreatment Naïve</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 800/200 mg q.d. <br/><br/><span class="indicationtitle">HIV InfectionTreatment Experienced</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400/100 mg (3 capsules or 5 mL suspension) b.i.d., increase dose to 533/133 mg (4 capsules or 6.5 mL) b.i.d., with concurrent
               efavirenz or nevirapine<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>6 mo12 y</i>, 715 kg, 12/3 mg/kg; 1540 kg, 10/2.5 mg/kg; &gt;40 kg, 400/100 mg b.i.d., increase dose 715 kg, 13/3.25 mg/kg;
               1540 kg, 11/2.75 mg/kg; &gt;40 kg, 533/133 mg b.i.d., with concurrent efavirenz or nevirapine<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p>
         			Note: Take with food.
         		
      </p><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with a meal or light snack.</li>
<li>
            				Note: If didanosine is concurrently ordered, give didanosine 1 h before or 2 h after lopinavir/ritonavir.
            			
         </li>
<li>Store refrigerated at 2°8° C (36°46° F). If stored at room temperature <img src="../images/special/lesserorequal.gif"/>25°
            C (77° F), discard after 2 mo.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Asthenia, pain. <span class="typehead">GI:</span> Abdominal pain, abnormal stools, <span class="speceff-common">diarrhea, nausea,</span> vomiting. <span class="typehead">CNS:</span> Headache, insomnia. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Flecainide,</b>
<b>propafenone,</b>
<b>pimozide</b> may lead to life-threatening arrhythmias; <b>rifampin</b> may decrease antiretroviral response; <b>dihydroergotamine,</b>
<b>ergonovine,</b>
<b>ergotamine,</b>
<b>methylergonovine</b> may lead to acute ergot toxicity; <span class="classification">hmg-coa reductase inhibitors</span> may increase risk of myopathy and rhabdomyolysis; <span class="classification">benzodiazepines</span> may have prolonged sedation or respiratory depression; <b>efavirenz,</b>
<b>nevirapine,</b>
<span class="classification">anticonvulsants</span>, <span class="classification">steroids</span> may decrease lopinavir levels; <b>delavirdine,</b>
<b>ritonavir</b> may increase lopinavir levels; may increase levels of <b>amprenavir,</b>
<b>indinavir,</b>
<b>saquinavir,</b>
<b>ketoconazole,</b>
<b>itraconazole,</b>
<b>midazolam,</b>
<b>triazolam,</b>
<b>rifabutin,</b>
<b>sildenafil,</b>
<b>atorvastatin,</b>
<b>cerivastatin,</b>
<span class="classification">immunosuppressants</span>; may decrease levels of <b>atovaquone,</b>
<b>methadone,</b>
<b>ethinyl estradiol.</b> Also see Interactions in <b>ritonavir</b> monograph. <span class="typehead">Herbal:</span>
<b>St. John's wort</b>, garlic may decrease <span class="classification">antiretroviral</span> activity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Increased absorption when taken with food. <span class="typehead">Peak:</span> 4 h. <span class="typehead">Distribution:</span> 9899% protein bound. <span class="typehead">Metabolism:</span> Extensively metabolized by CYP3A. <span class="typehead">Elimination:</span> Excreted primarily in feces. <span class="typehead"> Half-Life:</span>  56 h lopinavir. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of: Pancreatitis, especially with marked triglyceride elevations; new onset diabetes or loss of glycemic control;
            hypothyroidism or Cushing's syndrome.
         </li>
<li>Lab test: Periodically monitor fasting blood glucose, AST &amp; ALT, total cholesterol &amp; triglycerides, serum amylase, inorganic
            phosphorus, CBC with differential, and thyroid functions.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family</span></p>
<ul>
<li>Report all prescription and nonprescription drugs being taken. Do not use herbal products, especially St. John's wort, without
            first consulting the physician.
         </li>
<li>Become familiar with the potential adverse effects of this drug; report those that are bothersome to physician.</li>
<li>Concurrent use of sildenafil (Viagra) increases risk for adverse effects such as hypotension, changes in vision, and sustained
            erection; promptly report any of these to the physician.
         </li>
<li>Use additional or alternative contraceptive measures if estrogen-based hormonal contraceptives are being used.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>